Genotypes Associated With Reduced Activity of VKORC1 and CYP2C9 and Their Modification of Acenocoumarol Anticoagulation During the Initial Treatment Period-Reference-Cited by-同舟云学术

Genotypes Associated With Reduced Activity of VKORC1 and CYP2C9 and Their Modification of Acenocoumarol Anticoagulation During the Initial Treatment Period

Published:2009-02-18 Issue:4 Volume:85 Page:379-386
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:
Short-container-title:Clin Pharmacol Ther

Author:

Teichert M,van Schaik RHN,Hofman A,Uitterlinden AG,de Smet PAGM,Stricker BHCh,Visser LE

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Reference50 articles.

1. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

2. Current pharmacogenetic developments in oral anticoagulation therapy: The influence of variant VKORC1 and CYP2C9 alleles

3. A C1173T Dimorphism in the VKORC1 Gene Determines Coumarin Sensitivity and Bleeding Risk

4. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: Interaction between both genotypes affects overanticoagulation

5. Combination of Phenotype Assessments and CYP2C9-VKORC1 Polymorphisms in the Determination of Warfarin Dose Requirements in Heavily Medicated Patients

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacogenomics in Cardiovascular Diseases;Pharmacogenomics in Clinical Practice;2023

2. Genetic Associations With Stable Warfarin Dose Requirements in Han Chinese Patients;Journal of Cardiovascular Pharmacology;2021-07

3. Extremely low therapeutic doses of acenocoumarol in a patient with CYP2C9*3/*3 and VKORC1-1639A/A genotype;Pharmacogenomics;2019-04

4. Impact of CYP2C9 and VKORC1 Polymorphisms on Warfarin Sensitivity and Responsiveness in Jordanian Cardiovascular Patients during the Initiation Therapy;Genes;2018-11-27

5. Pharmacogenomics of Oral Antithrombotic Drugs;Current Pharmaceutical Design;2016-04-04